Teva Pharmaceutical Industries (TEVA) Stock Overview
Develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
TEVA Community Fair Values
Create NarrativeSee what 95 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Teva Pharmaceutical Industries Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$34.22 |
| 52 Week High | US$37.35 |
| 52 Week Low | US$12.47 |
| Beta | 0.72 |
| 1 Month Change | 7.58% |
| 3 Month Change | 38.15% |
| 1 Year Change | 104.42% |
| 3 Year Change | 245.31% |
| 5 Year Change | 218.03% |
| Change since IPO | 8,323.38% |
Recent News & Updates
Recent updates
Teva Is No Longer A Turnaround Story, It's A Growth One
Jan 14We Think Teva Pharmaceutical Industries' (NYSE:TEVA) Healthy Earnings Might Be Conservative
Nov 13
Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stock Catapults 26% Though Its Price And Business Still Lag The Industry
Nov 12Here's Why Teva Pharmaceutical Industries (NYSE:TEVA) Has A Meaningful Debt Burden
Jul 14Teva Pharmaceutical Industries Limited (NYSE:TEVA) Held Back By Insufficient Growth Even After Shares Climb 26%
May 17
Generics And Biosimilars Pipeline And Expansion Will Define Progress
The Pivot to Growth strategy targets revenue enhancement through product innovation, operational efficiency, and a sustainable generics business.Teva Pharmaceutical: A Risky Bet With Potential Upside
Feb 28Is Teva Pharmaceutical Industries (NYSE:TEVA) Using Too Much Debt?
Feb 27Teva Pharmaceutical: 2025 Guidance Sinks The Stock, But Presents An Opportunity
Jan 30Duvakitug And Teva's Growth: A Game Changer In Pharma
Dec 27Teva: Becoming Increasingly Solid, But No Longer Undervalued
Dec 04Teva: Great Time To Buy Leading Generic Drugmaker With Growth Indicators And Lower Debt
Oct 23Cheap Teva Stock Should Reward Patient Investors
Sep 09Teva's Transformation: From Generics Leader To Branded Drug Innovator
Aug 14Teva's Q2 Outlook: Key Developments In Biosimilars And Pipeline Drugs
Jul 26Teva Pharmaceutical: Buy This Bargain Before It's Gone
Jun 07Teva: Sustained Revenue Growth Amid Financial Strain (Rating Downgrade)
May 09Shareholder Returns
| TEVA | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0.7% | -1.3% | 1.0% |
| 1Y | 104.4% | 25.5% | 14.6% |
Return vs Industry: TEVA exceeded the US Pharmaceuticals industry which returned 25.5% over the past year.
Return vs Market: TEVA exceeded the US Market which returned 14.6% over the past year.
Price Volatility
| TEVA volatility | |
|---|---|
| TEVA Average Weekly Movement | 3.7% |
| Pharmaceuticals Industry Average Movement | 9.3% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TEVA has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: TEVA's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1901 | 32,008 | Richard Francis | www.tevapharm.com |
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, and oncology areas.
Teva Pharmaceutical Industries Limited Fundamentals Summary
| TEVA fundamental statistics | |
|---|---|
| Market cap | US$39.85b |
| Earnings (TTM) | US$1.41b |
| Revenue (TTM) | US$17.26b |
Is TEVA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TEVA income statement (TTM) | |
|---|---|
| Revenue | US$17.26b |
| Cost of Revenue | US$8.32b |
| Gross Profit | US$8.94b |
| Other Expenses | US$7.53b |
| Earnings | US$1.41b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.21 |
| Gross Margin | 51.79% |
| Net Profit Margin | 8.17% |
| Debt/Equity Ratio | 212.6% |
How did TEVA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/22 09:33 |
| End of Day Share Price | 2026/02/20 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Teva Pharmaceutical Industries Limited is covered by 46 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Balaji Prasad | Barclays |
| Glen Santangelo | Barclays |